NewBiologix, a technology innovation company pioneering efficient, cost-effective, and scalable production of viral vectors for gene and cell therapy, has launched a new U.S. subsidiary to better serve its growing customer base.
 
The new U.S. hub will offer real-time support and collaboration for gene and cell therapy companies in the world’s largest biotech market.
 
The company also appointed David Kelly as Business Development Manager to lead the U.S. operation and head business development. Kelly brings a blend of technical expertise and commercial acumen to NewBiologix. He has more than a decade of experience in gene and cell therapy, as well as stem cell manufacturing and commercial development. He will oversee sales and support for NewBiologix services and licensing opportunities for clients across the U.S. and Canada.
 
“I’m very pleased to return to the gene and cell therapy space as part of NewBiologix—an innovative, mission-driven company that is de-risking and significantly increasing efficiencies in gene and cell therapy production,” said Kelly. “I look forward to leading business development efforts as demand grows across U.S. biotech markets for our innovative products and services.”